Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)].
|
30673845 |
2019 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of the fusions was determined by RT-PCR in 71 classical PTC, 45 follicular variants of PTC (FVPTC), 19 follicular thyroid adenomas (FTAs) and 22 follicular thyroid carcinomas (FTCs).
|
29046324 |
2018 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC.
|
29108474 |
2018 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Skeletal muscle metastasis of papillary or follicular thyroid cancer (PTC/FTC) is a rare finding; only 11 cases of skeletal muscle PTC or FTC metastasis have been included in medical literature reviews.
|
29731874 |
2018 |
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sixty-five contralateral tumors were identified in 44 of 124 patients (35.5%) and included fvPTC (n = 40), classical PTC (n = 22), tall cell PTC (n = 2), and follicular carcinoma (n = 1).
|
28017809 |
2017 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The surgical resection specimen demonstrated FVPTC in 20 (74%) cases, classical type PTC in two (7%), solid variant of PTC in one (4%), and follicular thyroid carcinoma in four (15%).
|
28114855 |
2017 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several single-nucleotide polymorphisms (SNPs) have been associated with papillary and follicular thyroid cancer (PTC and FTC, respectively) risk, but few have replicated.
|
27207655 |
2016 |
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA was isolated from multinodular goiter (MNG; n=6), papillary carcinoma (PTC, n=14), follicular carcinoma (FC; n=5), and Hürthle cell carcinoma (HCC; n=7).
|
24559275 |
2014 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
German patients (n=253) with DTC (papillary thyroid carcinoma [PTC] and follicular thyroid carcinoma [FTC]) and HC (n=302) were genotyped for polymorphisms within the vitamin D metabolizing enzymes such as 25-hydroxylase (CYP2R1[rs12794714, rs10741657]), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1[rs10877012, rs4646536]), and 25-hydroxyvitamin D 24-hydrolase (CYP24A1[rs927650, rs2248137, rs2296241]).
|
22690899 |
2012 |
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the four possible outcomes (FTA, C-PTC, FV-PTC, and FTC), about 80% of FTA and C-PTC and 50% of FV-PTC and FTC samples were correctly assigned.
|
21778212 |
2011 |
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, chromosomal abnormalities are frequent in ATCs associated with FTC, but uncommon in those associated with PTC and in ATCs with no associated differentiated thyroid cancer.
|
12729478 |
2003 |
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whether a limited surgical approach is also justified in other cases, e.g. in any patient with intrathyroidal PTC or patients with micro-FTC (follicular thyroid carcinoma), remains to be shown and is the subject of ongoing investigations.
|
12192544 |
2002 |